Tekmira and Protiva to Merge; Agreement Ends Litigation, Expands RNAi Alliances

Although the companies have been at odds for years over the rights to a liposome-based drug-delivery technology, the transaction will end the wrangling. In conjunction with the deal, the new company will also receive $10 million in equity investments from Alnylam and Roche.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.